A recent retrospective study elucidates the correlation between breast cancer subtype and metastasis site, time to relapse, and patient survival.
The risk of bone metastases from GISTs, though rare, should be considered during long-term follow-up of patients, especially in those with liver metastases.
Researchers were able to demonstrate response to radiotherapy in breast cancer patients with osteolytic metastases by measuring increases in bone density.
A recent study found that radiation therapy was effective for the palliation of painful spinal metastases in patients with hepatocellular carcinoma.
An inhibitor of osteoclast formation can stop the proliferation of dormant tumor cells that in some breast cancer survivors turn into bone metastases.
Researchers at the Moffitt Cancer Center have created a computational model to simulate the bone metastasis process and to predict the outcomes of specific prostate cancer therapies.
This review will include discussion of the role of radiation therapy for osseous metastases and metastatic spinal cord compression, as well as the use of radiopharmaceuticals for painful osseous metastases.
As new data and new treatment options emerge, palliative radiotherapy algorithms will need to undergo continuous modifications and updates to ensure that patients receive optimal symptom relief.
Moving forward, perhaps no recent development in the use of RT in metastatic prostate cancer has captured greater attention than the use of radium-223 in metastatic castration-resistant prostate cancer (mCRPC).
In order to achieve maximum survival of patients with metastatic castration-resistant prostate cancer, the judicious use of all available effective agents and modalities is required. Both EBRT and radium-223 are effective at relieving pain, but both may decrease bone marrow function.